|
1
|
Finn RS: Current and future treatment
strategies for patients with advanced hepatocellular carcinoma:
Role of mTOR inhibition. Liver Cancer. 1:247–256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Gilabert M, Bruix J and Raoul
JL: Treatment of intermediate-stage hepatocellular carcinoma. Nat
Rev Clin Oncol. 11:525–535. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galmiche A, Chauffert B and Barbare JC:
New biological perspectives for the improvement of the efficacy of
sorafenib in hepatocellular carcinoma. Cancer Lett. 346:159–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang T and Hong W: Interorganellar
regulation of lysosome positioning by the Golgi apparatus through
Rab34 interaction with Rab-interacting lysosomal protein. Mol Biol
Cell. 13:4317–4332. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang T, Wong KK and Hong W: A unique
region of RILP distinguishes it from its related proteins in its
regulation of lysosomal morphology and interaction with Rab7 and
Rab34. Mol Biol Cell. 15:815–826. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang T and Hong W: Assay and functional
properties of Rab34 interaction with RILP in lysosome
morphogenesisMethods in Enzymology. Academic Press; New York, NY:
pp. 675–687. 2005, View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Starling GP, Yip YY, Sanger A, Morton PE,
Eden ER and Dodding MP: Folliculin directs the formation of a
Rab34-RILP complex to control the nutrient-dependent dynamic
distribution of lysosomes. EMBO Rep. 17:823–841. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Speight P and Silverman M:
Diacylglycerol-activated Hmunc13 serves as an effector of the
GTPase Rab34. Traffic. 6:858–865. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alloatti A, Kotsias F, Pauwels AM, Carpier
JM, Jouve M, Timmerman E, Pace L, Vargas P, Maurin M, Gehrmann U,
et al: Toll-like receptor 4 engagement on dendritic cells restrains
phago-lysosome fusion and promotes cross-presentation of antigens.
Immunity. 43:1087–1100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kasmapour B, Gronow A, Bleck CK, Hong W
and Gutierrez MG: Size-dependent mechanism of cargo sorting during
lysosome-phagosome fusion is controlled by Rab34. Proc Natl Acad
Sci USA. 109:pp. 20485–20490. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang HJ, Gao Y, Chen L, Li YL and Jiang
CL: RAB34 was a progression- and prognosis-associated biomarker in
gliomas. Tumour Biol. 36:1573–1578. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Salic A and Mitchison TJ: A chemical
method for fast and sensitive detection of DNA synthesis in vivo.
Proc Natl Acad Sci USA. 105:pp. 2415–2420. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goitre L: The Ras superfamily of small
GTPases: The unlocked secretsRas Signaling: Methods and Protocols.
Trabalzini L and Retta SF: Humana Press; Totowa, NJ: pp. 1–18.
2014, View Article : Google Scholar
|
|
14
|
Wennerberg K, Rossman KL and Der CJ: The
Ras superfamily at a glance. J Cell Sci. 118:843–846. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chan AM and Weber T: A putative link
between exocytosis and tumor development. Cancer Cell. 2:427–428.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wright PK: Targeting vesicle trafficking:
An important approach to cancer chemotherapy. Recent Patents
Anticancer Drug Discov. 3:137–147. 2008. View Article : Google Scholar
|
|
17
|
Chia WJ and Tang BL: Emerging roles for
Rab family GTPases in human cancer. Biochim Biophys Acta.
1795:110–116. 2009.PubMed/NCBI
|
|
18
|
Tong M, Chan KW, Bao JY, Wong KY, Chen JN,
Kwan PS, Tang KH, Fu L, Qin YR, Lok S, et al: Rab25 is a tumor
suppressor gene with antiangiogenic and anti-invasive activities in
esophageal squamous cell carcinoma. Cancer Res. 72:6024–6035. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dong WW, Mou Q, Chen J, Cui JT, Li WM and
Xiao WH: Differential expression of Rab27A/B correlates with
clinical outcome in hepatocellular carcinoma. World J
Gastroenterol. 18:1806–1813. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Murray AW: Recycling the cell cycle:
Cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sears RC and Nevins JR: Signaling networks
that link cell proliferation and cell fate. J Biol Chem.
277:11617–11620. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nieto MA and Cano A: The
epithelial-mesenchymal transition under control: Global programs to
regulate epithelial plasticity. Semin Cancer Biol. 22:361–368.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
